Twenty Years In Early Stage Biotech VC (Part 2): People Continuing in the trifecta of anniversary blogs, here are a few observations on people, talent and teams: · The power of luck! · Life is short… live by the NAR (No Asshole Rule) · By the time you know you need a

Turns out our Series A grew larger. All the more reason @LilaSciences is an exciting new frontier AI lab, and one of the top places in the world to work on on open-ended discovery.

Genomics team keeps cooking!

New🎙️What can you do for a mom facing an unexpected pregnancy? Gina Tomes has dedicated more than three decades to walking alongside women and families facing unexpected pregnancies and championing life. After the fall of Roe v. Wade, Gina recognized the urgent need to expand the

I'm looking for the "Anduril" of Bio. Anyone know any Bio-Defense startups?

In more pharma-AI bio partnership news: Takeda has signed a second deal with Nabla Bio @SurgeBiswas described Nabla's latest AI model, JAM, like an "autocomplete for molecules." https://t.co/av4eTs2Bv2

Clinical trials are a vital step in the development of new medicines. Unfortunately, we're not very good at enrolling patients in them. We run more clinical trials than ever, yet the vast majority of studies fail to hit their enrollment deadlines. It’s a crisis that slows

🔥 Don’t miss the fireside chat at our @PunchbowlNews event on Oct. 20! @AmericaInvests Council’s Will Dunham will join Anna Palmer to discuss how private capital supports jobs & small businesses.

when two awesome companies join forces

@dr_alphalyrae Anita is building an awesome company to do this

gettin nerdy, having fun always ✌️🧬

The answer is skin cells. Skin cells! That seems really odd, but lots of cells share lots of components and processes that are used in different ways in different cell types. And not-fun fact: psychotic symptoms are associated with skin abnormalities.

15 years in the making, we confirmed that mitochondria -the powerhouse of the cell- have an unusual localization in patients who experience psychosis (including schizophrenia and bipolar disorders). You’ll never guess what kind of patient cells we used to make this discovery...🧵

Starting a software co is like building a plane & trying to get it to lift off before you run out of runway Starting a biotech co is like trying to solve an escape room before time runs out For software co, getting the plane off the ground requires primarily ppl who can work

i am still of the opinion that solving the boring operational problems in biopharma r&d, like slowness in regulatory documentation and process development is the most effective way to derive value from AI in the short term

Bacterially grown living materials with resistant and on-demand functionality | Science Advances https://t.co/vTERXjCsfW

https://t.co/GRKumi7nU3

Check out our recent work on how researchers can collaboratively train AI models to predict protein properties such as subcellular location, without moving sensitive data across institutions, using @nvidia FLARE and @NVIDIAHealth BioNeMo Framework

The proteins in our blood as fingerprints for 59 diseases and health @ScienceMagazine https://t.co/02MgtnDqp6

Yeah, I am as excited as the next guy about creating an “AI scientist”, but I know all too well that for decades intelligence has not been the main bottleneck for creating better and more advanced scientific breakthroughs. We’ve been churning out more science PhDs than we knew

CRISPR came from yogurt bacteria. GLP-1s came from Gila monster venom. Taq polymerase came from hot spring bacteria. As much as we like to think that progress in biotech is driven by human design, our biggest breakthroughs over the years have all originated from nature.

TusoAI: Agentic Optimization for Scientific Methods